Brimonidine clinical trials
Also written Alphagan and Mirvaso.
Counted the way a researcher would: Brimonidine with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How each study uses brimonidine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the brimonidine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 6 Sept 1996 · ALPHAGAN · NDA 020613 (FDA, Drugs@FDA)
- European Union
- 20 Feb 2014 · Mirvaso · EMEA/H/C/002642 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
99 studies that test it; most in 2016 (11); 1 more planned to start later
| Year | Studies |
|---|---|
| 1998 | 1 |
| 1999 | 1 |
| 2003 | 3 |
| 2004 | 1 |
| 2005 | 5 |
| 2006 | 4 |
| 2008 | 8 |
| 2009 | 7 |
| 2010 | 6 |
| 2011 | 8 |
| 2012 | 4 |
| 2013 | 2 |
| 2014 | 6 |
| 2015 | 1 |
| 2016 | 11 |
| 2017 | 3 |
| 2018 | 4 |
| 2019 | 6 |
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 7 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 4 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 49 · Other 55
Allergan (17) · Galderma R&D (9) · Bausch & Lomb Incorporated (7) · Visus Therapeutics (3) · Wake Forest University Health Sciences (3) · Ocugen (3) · Massachusetts Eye and Ear Infirmary (3) · Eye Therapies, LLC (3)
Often tested with
Tested in the same studies.
Timolol (10) · Dorzolamide (6) · Latanoprost (5) · Carbachol (3) · Bimatoprost (3) · Acetazolamide (3) · Brinzolamide (3) · Travoprost (2)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test brimonidine.
- Jul 2027Brimonidine Eye Drops in the Prevention of Myopia ProgressionPhase 2 · Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
- Aug 2027Upneeq vs. Lumify PtosisPhase 4 · Duke University
Studies
Open first, then newest update. How each study uses brimonidine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 104
- Brimonidine Eye Drops in the Prevention of Myopia ProgressionRecruitingPhase 2Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y CajalNCT06996236Written as Treatment with brimonidine eye drops 0.025%
- The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma PatientsNot yet recruitingPhase 4Tulane UniversityNCT04007276Written as brimonidine tartrate ophthalmic solution 0.025%
- Upneeq vs. Lumify PtosisNot yet recruitingPhase 4Duke UniversityNCT07390578Written as Brimonidine 0.025% (Lumify)
- Safety and Efficacy Study of TAR-0520 Gel in Prevention of Taxane-induced Peripheral NeuropathyNot yet recruitingPhase 2Tarian PharmaNCT07082764Written as Brimonidine gel
- TAR-0520 Gel in EGFR Inhibitor-induced FolliculitisRecruitingPhase 2Tarian PharmaNCT06818058Written as Brimonidine tartrate Gel
- Phase 3 Evaluation of the Safety and Efficacy of LNZ100 & LNZ101 for the Treatment of PresbyopiaCompletedPhase 3LENZ Therapeutics, IncNCT05656027Written as Aceclidine+Brimonidine combination ophthalmic solution
- Safety and Efficacy Study of BRIMOCHOL™, BRIMOCHOL™ F, and Carbachol in Subjects With Emmetropic Phakic and Pseudophakic PresbyopiaCompletedPhase 2Visus TherapeuticsNCT04774237Written as BRIMOCHOL™ F
- Brimonidine 0.33% for Rosacea-Related Facial ErythemaCompletedPhase 4Istanbul Training and Research HospitalNCT07431476Written as Brimonidine 0.33% gel
- Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic PresbyopiaCompletedPhase 3Visus TherapeuticsNCT05135286Written as BRIMOCHOL™ PF
- Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic SolutionCompletedPhase 3Bausch & Lomb IncorporatedNCT05815758Written as Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo)
- Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic ConjunctivitisCompletedPhase 3Bausch & Lomb IncorporatedNCT05591755Written as Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution
- Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic ConjunctivitisCompletedPhase 3Bausch & Lomb IncorporatedNCT05579730Written as Brimonidine tartrate 0.025%/ketotifen fumarate 0.035%
- Brimonidine for Intraoperative HemostasisWithdrawnPhase 4University of LouisvilleNCT05480098Written as Brimonidine Topical
- Optic Nerve Perfusion Following Treatment with Latanoprost Versus Brimionidin TartrateCompletedEarly Phase 1Zagazig UniversityNCT06730516Written as Brimonidine 0.2 %
- Safety and Efficacy Study BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic or Pseudophakic PresbyopiaCompletedPhase 3Visus TherapeuticsNCT05270863Written as BRIMOCHOL™ PF
- "Efficacy and Safety of Brimonidine Tartrate Preservative-Free Formulation in Adults With Ocular Redness"CompletedPhase 3Bausch & Lomb IncorporatedNCT05360784Written as Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation
- The Effect of BrimonidineCompletedPhase 4Wake Forest University Health SciencesNCT03959176Written as Brimonidine
- Aqueous Humor Dynamics and BrimonidineCompletedEarly Phase 1University of NebraskaNCT01144494Written as Brimonidine
- Mirvaso® Gel and Dysport® for Erythema and Flushing of RosaceaTerminatedNot applicableSkin Laser & Surgery SpecialistsNCT03508869Written as Mirvaso® (brimonidine) topical gel, 0.33%
- Mirvaso in Use StudyCompletedPhase 4Galderma R&DNCT02249065Written as Brimonidine
See all 104 studies that test brimonidine →
Given beside what is tested · 7 — brimonidine is usual care or a partner of the new treatment
- Phase 3 Efficacy Study of LNZ100 & LNZ101 for the Treatment of PresbyopiaCompletedPhase 3LENZ Therapeutics, IncNCT05728944Written as Aceclidine+Brimonidine combination ophthalmic solution
- Phase 3 Safety Study of LNZ100 and LNZ101 for the Treatment of Presbyopia SubjectsCompletedPhase 3LENZ Therapeutics, IncNCT05753189Written as Aceclidine+Brimonidine combination ophthalmic solution
- Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the PresbyopiaCompletedPhase 3Corxel PharmaceuticalsNCT06045299Written as Aceclidine+Brimonidine combination ophthalmic solution
- Evaluation of the Safety and Effectiveness of Aceclidine (LNZ101) and Aceclidine + Brimonidine (LNZ100) in the Treatment of PresbyopiaCompletedPhase 2LENZ Therapeutics, IncNCT05431543Written as Aceclidine+Brimonidine combination ophthalmic solution
- Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of PresbyopiaCompletedPhase 2LENZ Therapeutics, IncNCT05294328Written as Aceclidine+Brimonidine combination ophthalmic solution
- Plasma Pharmacokinetics and Safety of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With PresbyopiaCompletedPhase 1LENZ Therapeutics, IncNCT05936489Written as Aceclidine + Brimonidine
- Finacea 15% and Brimonidine 0.33% Gel in the Treatment of Rosacea - A Pilot StudyCompletedPhase 4Derm Research, PLLCNCT02147691Written as Brimonidine 0.33%
As the comparator · 9 — what is tested is compared with brimonidine
- A Study Comparing the Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% With Sodium Hyaluronate Relative to Lumify in Adult Subjects With Ocular RednessCompletedPhase 3Bausch & Lomb IncorporatedNCT06803654Written as Lumify®
- Effect of Netarsudil vs Brimonidine in NTG Patients on LatanoprostCompletedPhase 4Westlake Eye SpecialistsNCT06449352Written as Brimonidine
- PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM)TerminatedPhase 3Laboratorios Sophia S.A de C.V.NCT03193333Written as Brimonidine Ophthalmic Solution
- Efficacy and Safety of Brinzolamide/Brimonidine Fixed Combination BID Compared to Brinzolamide BID Plus Brimonidine BID in Subjects With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)CompletedPhase 3Alcon ResearchNCT02339584Written as Brimonidine 2 mg/mL eye drops, solution
- A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular HypertensionCompletedPhase 2AllerganNCT01863953Written as Brimonidine Tartrate Ophthalmic Solution 0.2%
- Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID Plus Brimonidine BID in Patients With Open Angle Glaucoma or Ocular HypertensionCompletedPhase 3Alcon ResearchNCT01309204Written as Brimonidine tartrate 0.2% ophthalmic solution
- Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID and Brimonidine BID in Patients With Open Angle Glaucoma or Ocular HypertensionCompletedPhase 3Alcon ResearchNCT01310777Written as Brimonidine tartrate 0.2% ophthalmic solution
- Intraocular Pressure (IOP) Lowering Effect of Selective Laser Trabeculoplasty Versus Prostaglandin Analogues in Angle Closure GlaucomaStatus unknownPhase 3Singapore Eye Research InstituteNCT01004900Written as Travoprost/ Timolol/ Azopt/ Brimonidine
- Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular HypertensionCompletedPhase 3AllerganNCT00652106Written as Brimonidine 0.2% ophthalmic solution
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting1
- Brimonidine Eye Drops in the Prevention of Myopia ProgressionNov 9, 2026NCT06996236
Codes
What other systems call brimonidine · ClinicalTrials.gg INT006513
- MeSH (NLM) D000068438Brimonidine TartrateConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) E6GNX3HHTEBRIMONIDINEConfirmed FDA, NLM, Wikidata
- RxNorm 134615Confirmed FDA, Wikidata
- Wikidata Q577377brimonidineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C65269BrimonidineOne source FDA
- DrugBank DB00484One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000068438 | Brimonidine Tartrate | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | E6GNX3HHTE | BRIMONIDINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 134615 | — | Confirmed FDA, Wikidata |
| Wikidata | Q577377 | brimonidine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C65269 | Brimonidine | One source FDA |
| DrugBank | DB00484 | — | One source Wikidata |
Also registered as brimonidine tartrate (UNII 4S9CL2DY2H · RxNorm 39171).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.